• Molecule designated as DBPR112 (Sponsor: National Health Research Institutes, Taiwan), one of my invention covered by the patents, is approved (IND 128699; April 8th, 2016) by US Food and Drug Administration for testing in humans for the treatment of Cancer; DBPR112 is undergoing Phase I clinical trials in Taiwan for patients with head and neck cancer and EGFR mutated lung cancer (ClinicalTrials.gov Identifier: NCT03246854)
• Another molecule designated as DBPR114 is approved by US and Taiwan FDA in July and November 2017 for testing in humans for the treatment of Cancer